Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

Stopped Terminated for Commercial Reasons. There were no safety issues involved in the decision to terminate the study.

Conditions

• Neuromuscular Disease

Interventions

• DRUG: A0001 (alpha-tocopherolquinone)
• DRUG: Placebo

Sponsor

Penwest Pharmaceuticals Co.